PE20240691A1 - Compuestos moduladores de gcn2 y usos de los mismos - Google Patents
Compuestos moduladores de gcn2 y usos de los mismosInfo
- Publication number
- PE20240691A1 PE20240691A1 PE2023002158A PE2023002158A PE20240691A1 PE 20240691 A1 PE20240691 A1 PE 20240691A1 PE 2023002158 A PE2023002158 A PE 2023002158A PE 2023002158 A PE2023002158 A PE 2023002158A PE 20240691 A1 PE20240691 A1 PE 20240691A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- halogen
- membered
- gcn2
- membered bicyclic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101000926525 Homo sapiens eIF-2-alpha kinase GCN2 Proteins 0.000 title abstract 2
- 102100034175 eIF-2-alpha kinase GCN2 Human genes 0.000 title abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000004452 carbocyclyl group Chemical group 0.000 abstract 1
- -1 chloro, methyl Chemical group 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001153 fluoro group Chemical group F* 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Holo Graphy (AREA)
- Liquid Crystal Substances (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente invencion se proporcionan compuestos, composiciones y metodos utiles para modular la actividad de GCN2 y para tratar condiciones, enfermedades y trastornos relacionados (por ejemplo, cancer y enfermedades neurodegenerativas). Se refiere mas especificamente a un compuesto representado por la formula (Ia) o una sal farmaceuticamente aceptable del mismo, caracterizado porque: C es heterociclilo biciclico de 7-10 miembros, heteroarilo biciclico de 8 miembros o heteroarilo biciclico de 9 miembros, entre otros; X se selecciona del grupo que consiste en CH, C(R8), y N; R4 es halogeno, alquilo de C1-6, cicloalquilo de C3-6, entre otros; R5 es H, halogeno, alquilo de C1-6, entre otros; R6 es halogeno, alquilo de C1-6, ciano, entre otros; R7 se selecciona del grupo que consiste en fluoro, cloro, metilo, y ciano; R8 es halogeno, alquilo de C1-6, cicloalquilo de C3-6, entre otros; o cuando X es C(R8), R8 y R5 se pueden combinar opcionalmente junto con los atomos a los cuales se unen para formar un carbociclilo de 3-7 miembros, heterociclilo de 3-7 miembros o heteroarilo de 5-10 miembros, en donde estos pueden ser sustituidos opcionalmente en uno o mas carbonos disponibles por uno, dos, tres o mas sustituyentes hidroxilo; en donde, si el carbociclilo de 3-7 miembros, heterociclilo de 3-7 miembros o heteroarilo de 5-10 miembros contiene un atomo de nitrogeno de anillo sustituible, ese atomo de nitrogeno de anillo se puede sustituir opcionalmente por alquilo de C1-6.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140314P | 2021-01-22 | 2021-01-22 | |
| PCT/US2022/013383 WO2022159746A1 (en) | 2021-01-22 | 2022-01-21 | Gcn2 modulating compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240691A1 true PE20240691A1 (es) | 2024-04-10 |
Family
ID=80446635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023002158A PE20240691A1 (es) | 2021-01-22 | 2022-01-21 | Compuestos moduladores de gcn2 y usos de los mismos |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240083897A1 (es) |
| EP (1) | EP4281182A1 (es) |
| JP (1) | JP2024504364A (es) |
| KR (1) | KR20240021143A (es) |
| CN (1) | CN117203206A (es) |
| AU (1) | AU2022210760A1 (es) |
| BR (1) | BR112023014723A2 (es) |
| CA (1) | CA3209124A1 (es) |
| CO (1) | CO2023010940A2 (es) |
| CR (1) | CR20230408A (es) |
| IL (1) | IL304611A (es) |
| MX (1) | MX2023008589A (es) |
| PE (1) | PE20240691A1 (es) |
| WO (1) | WO2022159746A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB202008749D0 (en) | 2020-06-09 | 2020-07-22 | Ip2Ipo Innovations Ltd | Novel compounds |
| CA3254600A1 (en) * | 2022-05-25 | 2023-11-30 | Hibercell, Inc. | GCN2 MODULATOR FOR CANCER TREATMENT |
| WO2024077092A1 (en) * | 2022-10-04 | 2024-04-11 | Hibercell, Inc. | Gcn2 inhibitor for treating metastases |
| EP4652170A1 (en) * | 2023-01-20 | 2025-11-26 | Hibercell, Inc. | Crystalline forms of 6-(3-((5-chloro-2-methoxypyridine)-3- sulfonamido)-2,6-difluorophenyl)-n-methylimidazo[l,5- ajpyrazine-l-carboxamide and methods for using the same |
| WO2025122985A1 (en) * | 2023-12-08 | 2025-06-12 | Hibercell, Inc. | Methods of treating acute myeloid leukemia using combinations of gcn2 modulators, venetoclax, and azacitidine |
| WO2025137710A1 (en) * | 2023-12-22 | 2025-06-26 | Hibercell, Inc. | Methods of treating cancer using combinations of gcn2 modulators and belzutifan |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0415210A (pt) * | 2003-10-08 | 2006-12-05 | Irm Llc | compostos e composições como inibidores de proteìna cinase |
| WO2010070060A1 (en) * | 2008-12-19 | 2010-06-24 | Nerviano Medical Sciences S.R.L. | Bicyclic pyrazoles as protein kinase inhibitors |
| MA45940B1 (fr) * | 2016-08-10 | 2024-12-31 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique |
| US10988477B2 (en) * | 2018-01-29 | 2021-04-27 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| WO2020210828A1 (en) * | 2019-04-12 | 2020-10-15 | Hibercell, Inc. | (aza)indazolyl-aryl sulfonamide and related compounds and their use in treating medical conditions |
| EP4107146A1 (en) * | 2020-02-17 | 2022-12-28 | Alesta Therapeutics BV | Gcn2 modulator compounds |
-
2022
- 2022-01-21 JP JP2023544292A patent/JP2024504364A/ja active Pending
- 2022-01-21 CN CN202280022926.3A patent/CN117203206A/zh active Pending
- 2022-01-21 EP EP22704111.8A patent/EP4281182A1/en active Pending
- 2022-01-21 KR KR1020237028260A patent/KR20240021143A/ko active Pending
- 2022-01-21 BR BR112023014723A patent/BR112023014723A2/pt unknown
- 2022-01-21 CA CA3209124A patent/CA3209124A1/en active Pending
- 2022-01-21 PE PE2023002158A patent/PE20240691A1/es unknown
- 2022-01-21 AU AU2022210760A patent/AU2022210760A1/en active Pending
- 2022-01-21 US US18/262,493 patent/US20240083897A1/en active Pending
- 2022-01-21 CR CR20230408A patent/CR20230408A/es unknown
- 2022-01-21 WO PCT/US2022/013383 patent/WO2022159746A1/en not_active Ceased
- 2022-01-21 MX MX2023008589A patent/MX2023008589A/es unknown
-
2023
- 2023-07-20 IL IL304611A patent/IL304611A/en unknown
- 2023-08-22 CO CONC2023/0010940A patent/CO2023010940A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230408A (es) | 2024-05-07 |
| EP4281182A1 (en) | 2023-11-29 |
| CN117203206A (zh) | 2023-12-08 |
| KR20240021143A (ko) | 2024-02-16 |
| WO2022159746A1 (en) | 2022-07-28 |
| CO2023010940A2 (es) | 2023-12-11 |
| BR112023014723A2 (pt) | 2023-10-03 |
| IL304611A (en) | 2023-09-01 |
| JP2024504364A (ja) | 2024-01-31 |
| US20240083897A1 (en) | 2024-03-14 |
| CA3209124A1 (en) | 2022-07-28 |
| MX2023008589A (es) | 2023-08-09 |
| AU2022210760A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20240691A1 (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| PE20240687A1 (es) | Compuestos de indazol como inhibidores de cinasas | |
| PE20240765A1 (es) | Compuestos para la inhibicion de nlrp3 y usos de estos | |
| PE20240775A1 (es) | Compuestos antivirales | |
| PE20251288A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20250674A1 (es) | Compuestos heterociclicos como inmunomoduladores | |
| PE20190437A1 (es) | Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| CU24448B1 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| PE20220567A1 (es) | Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| CL2021003573A1 (es) | Compuestos y métodos que inhiben eif4e | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR110122A1 (es) | Fenoxitriazoles | |
| AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| AR123435A1 (es) | Derivados de sulfamoil urea que contienen resto alquilo-oxacicloalquilo, y usos de los mismos | |
| AR104533A1 (es) | Derivados de ácido ciclopropano carboxílico y sus usos como inhibidores de leucotrieno c₄ sintasa | |
| PE20251600A1 (es) | Compuestos que contienen heteroatomos y usos de estos |